This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A of the study will find out how much and how frequently PRO1184 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1184 is and if it works to treat solid tumor cancers.
2 Primary · 8 Secondary · Reporting Duration: Up to approximately 2 years.
134 Total Participants · 1 Treatment Group
Primary Treatment: PRO1184 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: